To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Evans formally abandons early stage biotech
Sir Christopher Evans has rebranded his firm Merlin Biosciences as Excalibur as he focuses more broadly across the medical sector with a number of planned funds.
